|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-6-30
|
|
pubmed:abstractText |
The incidence of malignant melanoma is increasing by about 2-5% per year, exceeding an incidence of all other tumors. Adjuvant immunotherapy with high-dose interferon (HDI) as per the ECOG 1684 trial Kirkwood's schema is still recommended as a standard. HDI should be started within 60 days after a surgical procedure. Meaningful adjuvant immunotherapy is based on radical surgical excision, an investigation of the sentinel node and regional lymph node dissection, if indicated. Current research aims to utilize routinely usable biomarkers in order to define patients who would explicitly profit from HDI.
|
|
pubmed:language |
cze
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0862-495X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
180-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
[High-dose interferon alpha in treatment of patients with malignant melanoma, monitoring of predictive and prognostic biomarkers].
|
|
pubmed:affiliation |
Klinika onkologie a radioterapie, LF UK a FN Hradec Králové. Jaja.vanaskova@seznam.cz
|
|
pubmed:publicationType |
Journal Article,
English Abstract,
Review
|
